Signos, a San Francisco, CA-based provider of a metabolic health platform, raised $20M in Series B funding.
The round was led by Cheyenne Ventures and GV (Google Ventures), with additional funding from Dexcom Ventures and Samsung Next.
The company intends to use the funds to expand its core team and platform and conduct additional research on metabolic health.
Led by Sharam Fouladgar-Mercer, CEO, Signos combines continuous glucose information with an AI-enhanced app to offer data and recommendations designed to drive healthy and sustained weight loss. The app enables members to log what they eat and how much they exercise, allowing the Signos AI platform to learn how one’s metabolism reacts to different foods and fitness patterns. Signos then provides data-driven personalized recommendations based on an individual’s unique metabolic profile. “Sleep, stress, exercise, and diet all influence how high and sustained one’s glucose spikes can be. By providing glucose visibility, tracking and AI-driven proactive suggestions, Signos can help users navigate those choices for better health.
The company currently offers a metabolic-led solution to reverse prediabetes and aid those on their weight loss journey. Previously only available for non-diabetics, Signos expanded its weight management platform to support people living with Type 2 diabetes in May 2023.
FinSMEs
24/10/2023